The question of whether “Big Food” companies are hiding links between diet and memory loss taps into a complex and controversial intersection of nutrition science, corporate interests, and public health. While there is no definitive proof that large food corporations…
PFAS contamination is increasingly being scrutinized for its potential role in a wide range of serious health problems, and there is growing concern that it could become the next major wave of lawsuits similar to those seen with Alzheimer’s disease.…
Several states in the United States are actively pursuing legal action against companies responsible for producing and distributing toxic chemicals linked to serious health issues, including dementia. These lawsuits focus primarily on a class of chemicals known as PFAS (per-…
Donald Trump’s health, particularly concerns about cognitive decline and dementia, has been a topic of intense public and professional scrutiny. Some clinical psychologists and experts have observed signs that suggest he may be experiencing neurological deterioration, including symptoms consistent with…
The question of whether Dr. Anthony Fauci’s legacy is tied to failed Alzheimer’s research funding involves examining his role, influence, and the broader context of biomedical research funding, particularly at the National Institute of Allergy and Infectious Diseases (NIAID), which…
Hospitals can indeed face lawsuits for the misdiagnosis of Alzheimer’s disease, as misdiagnosis falls under the broader category of medical malpractice when it results from negligence or failure to meet the standard of care. Alzheimer’s disease is a complex neurodegenerative…
Nursing homes caring for dementia patients face complex challenges, especially when it comes to managing behaviors that can be difficult or dangerous. One controversial and serious issue is the use of physical or chemical restraints on these patients. The question…
Pharmaceutical executives could potentially face class action lawsuits related to failed Alzheimer’s drug trials, especially if there is evidence suggesting misconduct, misrepresentation, or negligence in the development, testing, or marketing of these drugs. Alzheimer’s disease is a devastating neurodegenerative condition…
The question of whether the U.S. Department of Health and Human Services (HHS) is fast-tracking experimental dementia drugs that do not work is complex and involves understanding the drug approval process, recent developments in dementia drug research, and controversies surrounding…
The question of whether states will sue the federal government over cuts to Alzheimer’s funding is unfolding amid a broader context of significant federal reductions in health and research grants, which have already prompted legal challenges and political pushback from…